1
|
Graham B, Jin Y, Bazeley P, Husni E, Calabrese LH. Online, low-volume meditation does not alter immune-related biomarkers. Brain Behav Immun Health 2022; 26:100531. [PMID: 36267832 PMCID: PMC9576541 DOI: 10.1016/j.bbih.2022.100531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 09/08/2022] [Accepted: 10/01/2022] [Indexed: 11/09/2022] Open
Abstract
Objectives Prior studies of mindfulness meditation have demonstrated anti-inflammatory and immunoregulatory effects but whether meditation courses delivered online can exert similar effects is poorly understood. Barriers to large scale implementation of traditional mindfulness meditation programs has created an increased interest in the effect of less time- and resource-intensive online meditation courses. The purpose of this study was to determine whether a 6-week online mindfulness program with low time demands on nurses would lead to changes in gene expression, cytokine profiles, telomerase activity, and cortisol profiles. Methods This was a randomized, parallel pilot study comparing an online mindfulness-based stress management program to an active control group from December 2018 to May 2019. Healthy nurses with above average levels of perceived stress were randomized to receive a 6-week online mindfulness-based stress management program including ≥5 min daily meditation practice or listen to relaxing music for ≥5 min daily as the control arm. Blood samples were collected at baseline and after 6 weeks, and various self-reported measures of stress, physical and emotional health were collected at baseline, after 6 weeks, and after 12 weeks. Whole transcriptome mRNA sequencing of whole blood at baseline and after 6 weeks was performed along with measurement of plasma IL-6, IL-8, IL-10, TNF-α, and IFN-γ. Peripheral blood mononuclear cells were isolated, and telomerase activity was measured. Diurnal salivary cortisol profiles were assessed at baseline and after 6 weeks. The primary outcome was change over time in a pre-determined set of 53 genes representative of the immune-related changes seen with stress, which was analyzed using a mixed linear model. Secondary outcomes included all other self-reported measures and biomarkers mentioned above. Results A total of 61 nurses were randomized, with 52 having sufficient data to include in the final analysis. After 6 weeks, nurses in the control group reported significant reductions in stress as measured by the Perceived Stress Scale while those in the mindfulness group did not. However, after 12 weeks, the mindfulness group also showed a significant reduction in stress. When compared to the control group, no significant changes in RNA gene expression or any other biomarkers were observed in the nurses who participated in the mindfulness program. Conclusions Our study found that this brief online mindfulness-based intervention was effective in reducing stress in nurses, albeit with a delayed effect compared to listening to relaxing music. Regarding immunoregulatory effects, there were no significant differences between treatment and control groups in transcriptomic or other tested biomarkers of immune function. This study provides evidence for a floor effect of mindfulness on transcriptional and circulating biomarkers of immune function.
Collapse
Key Words
- CRP, C-reactive protein
- CTRA, conserved ranscriptional response to adversity
- IFN-γ, interferon gamma
- IL-10, interleukin-10
- IL-6, interleukin-6
- IL-8, interleukin-8
- IRF-1, interferon regulatory factor 1
- NF-κB, nuclear factor kappa B
- PROMIS, patient-reported outcomes measurement information system
- PSS, perceived stress scale
- TNF-α, tumor necrosis factor alpha
Collapse
Affiliation(s)
- Brett Graham
- Cleveland Clinic Lerner College of Medicine, 9501 Euclid Ave./EC10, Cleveland, OH, 44195, USA,Corresponding author. Vanderbilt University Medical Center, Department of Neurology, 1161 21st Avenue South, A-0118 Medical Center North, Nashville, TN, 37232, USA.
| | - Yuxuan Jin
- Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, 9500 Euclid Ave. Cleveland, OH, 44195, USA
| | - Peter Bazeley
- Cleveland Clinic Lerner Research Institute, Department of Quantitative Health Sciences, 9500 Euclid Ave. Cleveland, OH, 44195, USA
| | - Elaine Husni
- Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology, 9500 Euclid Ave. Cleveland, OH, 44195, USA
| | - Leonard H. Calabrese
- Cleveland Clinic Orthopaedic & Rheumatologic Institute, 9500 Euclid Ave. Cleveland, OH, 44195, USA
| |
Collapse
|
2
|
Cianchetti S, Cardini C, Puxeddu I, Latorre M, Bartoli ML, Bradicich M, Dente F, Bacci E, Celi A, Paggiaro P. Distinct profile of inflammatory and remodelling biomarkers in sputum of severe asthmatic patients with or without persistent airway obstruction. World Allergy Organ J 2019; 12:100078. [PMID: 31871533 PMCID: PMC6911957 DOI: 10.1016/j.waojou.2019.100078] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 09/25/2019] [Accepted: 09/27/2019] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Both inflammatory and remodelling processes are associated with irreversible airway obstruction observed in severe asthma. Our aim was to characterize a group of severe asthmatic patients with or without persistent airway obstruction in relation to specific sputum inflammatory and remodelling biomarkers. METHODS Forty-five patients under regular high-dose inhaled corticosteroid/ß-2agonist treatment were studied, after a follow-up period of at least 2 years, with a minimum of 4 visits. Periostin, TGF-ß, RANTES, IL-8, GM-CSF, FGF-2, and cell counts were measured in induced sputum. Serum periostin was also measured. RESULTS Sputum induction was successfully performed in all but 5 patients. There were no significant differences in demographic and clinical data between patients with non-persistent obstruction (NO: FEV1/VC>88%pred.) and those with persistent obstruction (O: a not completely reversible obstruction with FEV1/VC<88%pred. at each visit before the study visit). Patients with persistent obstruction had significantly higher sputum periostin and TGF-ß concentrations than NO patients and a trend of higher serum periostin levels. GM-CSF and FGF-2 were significantly increased in NO compared to O patients. No differences between groups were found for RANTES, IL-8 and differential cell counts. Sputum periostin inversely correlated with functional parameters (prebronch. FEV1: rho = -0.36, p < 0.05; postbronch. FEV1: rho = -0.33, p = 0.05). Patients with high sputum periostin concentration (>103.3 pg/ml: median value) showed an absolute number of sputum eosinophils significantly higher than patients with low sputum periostin; this behavior was unobserved when serum periostin was considered. CONCLUSIONS Only periostin and TGF-ß identified a subgroup of severe asthmatic patients with persistent airway obstruction. Sputum periostin was also inversely associated with FEV1 and proved to be a more sensitive biomarker than serum periostin to identify severe asthmatics with higher sputum eosinophilia.
Collapse
Key Words
- Airway inflammation
- BMI, body mass index
- Biomarkers
- FEV1, forced expiratory volume in 1 s
- FGF-2, fibroblast growth factor-2
- FeNO, fraction of exhaled nitric oxide
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- ICS, inhaled corticosteroids
- IFN, interferon
- IL-8, interleukin-8
- Induced sputum
- LABA, long-acting ß-2agonist
- LTRA, leukotriene receptor antagonist
- RANTES, regulated on activation, normal T-cells expressed and secreted
- Remodelling
- Severe asthma
- TGF-ß, transforming growth factor-ß-1
- VC, vital capacity
Collapse
Affiliation(s)
- Silvana Cianchetti
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Cristina Cardini
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Ilaria Puxeddu
- Immunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Manuela Latorre
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Maria Laura Bartoli
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Matteo Bradicich
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Federico Dente
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Elena Bacci
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Alessandro Celi
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| | - Pierluigi Paggiaro
- Respiratory Pathophysiology Unit, Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy
| |
Collapse
|
3
|
Su T, Li F, Guan J, Liu L, Huang P, Wang Y, Qi X, Liu Z, Lu L, Wang D. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling. Phytomedicine 2019; 63:152968. [PMID: 31280140 DOI: 10.1016/j.phymed.2019.152968] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 04/30/2019] [Accepted: 05/21/2019] [Indexed: 05/21/2023]
Abstract
BACKGROUND Gastric cancer has a high morbidity and is a leading cause of cancer-related mortality worldwide. Helicobacter pylori (H. pylori) infection is commonly found in the early stage of gastric cancer pathogenesis, which induces chronic gastritis. Artemisinin (ART) and its derivatives (ARTS, artesunate and DHA, dihydroartemisinin), a new class of potent antimalarials, have been reported to exert both preventive and anti-gastric cancer effects. However, the underlying mechanisms of the chemopreventive effects of ART and its derivatives in H. pylori infection induced-gastric cancer are not fully elucidated. PURPOSE We investigated the effects of H. pylori infection in gastric cancer; and the preventive mechanisms of ART, ARTS and DHA. METHODS The H. pylori growth was determined by the broth macro-dilution method, and its adhesion to gastric cancer cells was evaluated by using the urease assay. The protein and mRNA levels, reactive oxygen species (ROS) production, as well as the production of inflammatory cytokines were evaluated by Western blot, real-time PCR, flow cytometry and ELISA, respectively. Moreover, an in vivo MNU (N-methyl-N-nitroso-urea) and H. pylori-induced gastric adenocarcinoma mouse model was established for the investigation of the cancer preventive effects of ART and its derivaties, and the underlying mechanisms of action. RESULTS ART, DHA and ARTS inhibited the growth of H. pylori and gastric cancer cells,suppressed H. pylori adhesion to the gastric cancer cells, and reduced the H. pylori-enhanced ROS production. Moreover, ART, DHA and ARTS significantly reduced tumor incidence, number of tumor nodules and tumor size in the mouse model. Among these three compounds, DHA exerted the most potent chemopreventive effect. Mechanistic studies showed that ART and its derivatives potently inhibited the NF-κB activation. CONCLUSION ART, DHA and ARTS have potent preventive effects in H. pylori-induced gastric carcinogenesis. These effects are, at least in part, attributed to the inhibition of NF-κB signaling pathway. Our findings provide a molecular justification of using ART and its derivatives for the prevention and treatment of gastric cancer.
Collapse
Key Words
- ARTS, artesunate
- Abbreviations: ART, artemisinin
- Artemisinin
- Artesunate
- CFU, colony forming units
- COX-2, cyclooxygenase-2
- DHA, dehydroartemisinin
- DMSO, dimethyl sulfoxide
- Dihydroartemisinin
- ELISA, enzyme-linked immunosorbent assay
- Gastric cancer
- Helicobacter pylori
- IARC, International Agency for Research on Cancer
- IL-8, interleukin-8
- MNU, N-methyl-N-nitroso-urea
- MOI, multiplicity of infection
- NF-κB signaling
- NF-κB, nuclear factor-κB
- PBS, phosphate buffer solution
- ROS, reactive oxygen species
- TNF-α, tumor necrosis factor-α
Collapse
Affiliation(s)
- Tao Su
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Fangyuan Li
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Jiaji Guan
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Linxin Liu
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Ping Huang
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Ying Wang
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Xiaoxiao Qi
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Zhongqiu Liu
- Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, Guangdong, China; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Linlin Lu
- Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, Guangdong, China; Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
| | - Dawei Wang
- Shunde Hospital of Guangzhou University of Chinese Medicine, Shunde, Guangdong, China.
| |
Collapse
|
4
|
Stamatopoulos A, Stamatopoulos T, Gamie Z, Kenanidis E, Ribeiro RDC, Rankin KS, Gerrand C, Dalgarno K, Tsiridis E. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. J Bone Oncol 2019; 16:100231. [PMID: 30956944 PMCID: PMC6434099 DOI: 10.1016/j.jbo.2019.100231] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Revised: 03/14/2019] [Accepted: 03/18/2019] [Indexed: 12/12/2022] Open
Abstract
Over the past few decades, there has been growing interest in understanding the molecular mechanisms of cancer pathogenesis and progression, as it is still associated with high morbidity and mortality. Current management of large bone sarcomas typically includes the complex therapeutic approach of limb salvage or sacrifice combined with pre- and postoperative multidrug chemotherapy and/or radiotherapy, and is still associated with high recurrence rates. The development of cellular strategies against specific characteristics of tumour cells appears to be promising, as they can target cancer cells selectively. Recently, Mesenchymal Stromal Cells (MSCs) have been the subject of significant research in orthopaedic clinical practice through their use in regenerative medicine. Further research has been directed at the use of MSCs for more personalized bone sarcoma treatments, taking advantage of their wide range of potential biological functions, which can be augmented by using tissue engineering approaches to promote healing of large defects. In this review, we explore the use of MSCs in bone sarcoma treatment, by analyzing MSCs and tumour cell interactions, transduction of MSCs to target sarcoma, and their clinical applications on humans concerning bone regeneration after bone sarcoma extraction.
Collapse
Key Words
- 5-FC, 5-fluorocytosine
- AAT, a1-antitrypsin
- APCs, antigen presenting cells
- ASC, adipose-derived stromal/stem cells
- Abs, antibodies
- Ang1, angiopoietin-1
- BD, bone defect
- BMMSCs, bone marrow-derived mesenchymal stromal cells
- Biology
- Bone
- CAM, cell adhesion molecules
- CCL5, chemokine ligand 5
- CCR2, chemokine receptor 2
- CD, classification determinants
- CD, cytosine deaminase
- CLUAP1, clusterin associated protein 1
- CSPG4, Chondroitin sulfate proteoglycan 4
- CX3CL1, chemokine (C-X3-C motif) ligand 1
- CXCL12/CXCR4, C-X-C chemokine ligand 12/ C-X-C chemokine receptor 4
- CXCL12/CXCR7, C-X-C chemokine ligand 12/ C-X-C chemokine receptor 7
- CXCR4, chemokine receptor type 4
- Cell
- DBM, Demineralized Bone Marrow
- DKK1, dickkopf-related protein 1
- ECM, extracellular matrix
- EMT, epithelial-mesenchymal transition
- FGF-2, fibroblast growth factors-2
- FGF-7, fibroblast growth factors-7
- GD2, disialoganglioside 2
- HER2, human epidermal growth factor receptor 2
- HGF, hepatocyte growth factor
- HMGB1/RACE, high mobility group box-1 protein/ receptor for advanced glycation end-products
- IDO, indoleamine 2,3-dioxygenase
- IFN-α, interferon alpha
- IFN-β, interferon beta
- IFN-γ, interferon gamma
- IGF-1R, insulin-like growth factor 1 receptor
- IL-10, interleukin-10
- IL-12, interleukin-12
- IL-18, interleukin-18
- IL-1b, interleukin-1b
- IL-21, interleukin-21
- IL-2a, interleukin-2a
- IL-6, interleukin-6
- IL-8, interleukin-8
- IL11RA, Interleukin 11 Receptor Subunit Alpha
- MAGE, melanoma antigen gene
- MCP-1, monocyte chemoattractant protein-1
- MMP-2, matrix metalloproteinase-2
- MMP2/9, matrix metalloproteinase-2/9
- MRP, multidrug resistance protein
- MSCs, mesenchymal stem/stromal cells
- Mesenchymal
- NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells
- OPG, osteoprotegerin
- Orthopaedic
- PBS, phosphate-buffered saline
- PDGF, platelet-derived growth factor
- PDX, patient derived xenograft
- PEDF, pigment epithelium-derived factor
- PGE2, prostaglandin E2
- PI3K/Akt, phosphoinositide 3-kinase/protein kinase B
- PTX, paclitaxel
- RANK, receptor activator of nuclear factor kappa-B
- RANKL, receptor activator of nuclear factor kappa-B ligand
- RBCs, red blood cells
- RES, reticuloendothelial system
- RNA, ribonucleic acid
- Regeneration
- SC, stem cells
- SCF, stem cells factor
- SDF-1, stromal cell-derived factor 1
- STAT-3, signal transducer and activator of transcription 3
- Sarcoma
- Stromal
- TAAs, tumour-associated antigens
- TCR, T cell receptor
- TGF-b, transforming growth factor beta
- TGF-b1, transforming growth factor beta 1
- TNF, tumour necrosis factor
- TNF-a, tumour necrosis factor alpha
- TRAIL, tumour necrosis factor related apoptosis-inducing ligand
- Tissue
- VEGF, vascular endothelial growth factor
- VEGFR, vascular endothelial growth factor receptor
- WBCs, white blood cell
- hMSCs, human mesenchymal stromal cells
- rh-TRAIL, recombinant human tumour necrosis factor related apoptosis-inducing ligand
Collapse
Affiliation(s)
- Alexandros Stamatopoulos
- Academic Orthopaedic Unit, Papageorgiou General Hospital, Aristotle University Medical School, West Ring Road of Thessaloniki, Pavlos Melas Area, N. Efkarpia, 56403 Thessaloniki, Greece
- Center of Orthopaedics and Regenerative Medicine (C.O.RE.), Center for Interdisciplinary Research and Innovation (C.I.R.I.), Aristotle University Thessaloniki, Greece
| | - Theodosios Stamatopoulos
- Academic Orthopaedic Unit, Papageorgiou General Hospital, Aristotle University Medical School, West Ring Road of Thessaloniki, Pavlos Melas Area, N. Efkarpia, 56403 Thessaloniki, Greece
- Center of Orthopaedics and Regenerative Medicine (C.O.RE.), Center for Interdisciplinary Research and Innovation (C.I.R.I.), Aristotle University Thessaloniki, Greece
| | - Zakareya Gamie
- Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
| | - Eustathios Kenanidis
- Academic Orthopaedic Unit, Papageorgiou General Hospital, Aristotle University Medical School, West Ring Road of Thessaloniki, Pavlos Melas Area, N. Efkarpia, 56403 Thessaloniki, Greece
- Center of Orthopaedics and Regenerative Medicine (C.O.RE.), Center for Interdisciplinary Research and Innovation (C.I.R.I.), Aristotle University Thessaloniki, Greece
| | - Ricardo Da Conceicao Ribeiro
- School of Mechanical and Systems Engineering, Stephenson Building, Claremont Road, Newcastle upon Tyne NE1 7RU, UK
| | - Kenneth Samora Rankin
- Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
| | - Craig Gerrand
- Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, HA7 4LP, UK
| | - Kenneth Dalgarno
- School of Mechanical and Systems Engineering, Stephenson Building, Claremont Road, Newcastle upon Tyne NE1 7RU, UK
| | - Eleftherios Tsiridis
- Academic Orthopaedic Unit, Papageorgiou General Hospital, Aristotle University Medical School, West Ring Road of Thessaloniki, Pavlos Melas Area, N. Efkarpia, 56403 Thessaloniki, Greece
- Center of Orthopaedics and Regenerative Medicine (C.O.RE.), Center for Interdisciplinary Research and Innovation (C.I.R.I.), Aristotle University Thessaloniki, Greece
| |
Collapse
|
5
|
Foley JH, Walton BL, Aleman MM, O'Byrne AM, Lei V, Harrasser M, Foley KA, Wolberg AS, Conway EM. Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine 2016; 5:175-82. [PMID: 27077125 PMCID: PMC4816834 DOI: 10.1016/j.ebiom.2016.02.011] [Citation(s) in RCA: 93] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 02/04/2016] [Accepted: 02/05/2016] [Indexed: 12/20/2022] Open
Abstract
Thrombus formation leading to vaso-occlusive events is a major cause of death, and involves complex interactions between coagulation, fibrinolytic and innate immune systems. Leukocyte recruitment is a key step, mediated partly by chemotactic complement activation factors C3a and C5a. However, mechanisms mediating C3a/C5a generation during thrombosis have not been studied. In a murine venous thrombosis model, levels of thrombin–antithrombin complexes poorly correlated with C3a and C5a, excluding a central role for thrombin in C3a/C5a production. However, clot weight strongly correlated with C5a, suggesting processes triggered during thrombosis promote C5a generation. Since thrombosis elicits fibrinolysis, we hypothesized that plasmin activates C5 during thrombosis. In vitro, the catalytic efficiency of plasmin-mediated C5a generation greatly exceeded that of thrombin or factor Xa, but was similar to the recognized complement C5 convertases. Plasmin-activated C5 yielded a functional membrane attack complex (MAC). In an arterial thrombosis model, plasminogen activator administration increased C5a levels. Overall, these findings suggest plasmin bridges thrombosis and the immune response by liberating C5a and inducing MAC assembly. These new insights may lead to the development of strategies to limit thrombus formation and/or enhance resolution. Thrombin is not a major direct contributor to C5a generation during venous thrombosis in mice. Plasmin, a protease generated in response to thrombin generation and fibrin deposition, efficiently cleaves C5 to C5a. In an arterial thrombosis model, administration of a plasminogen activator augments C5a plasma levels. Plasmin participates in immunothrombosis, liberating chemotactic C5a and inducing assembly of the procoagulant C5b-9.
Venous and arterial thrombosis are major causes of death and morbidity. Leukocytes are early and active participants in thrombus formation, recruited partly by complement factor C5a. We examined how C5a is generated in the setting of thrombosis. In venous thrombosis in mice, we show that thrombin, a key clot-promoting enzyme, is not a major contributor to C5a generation. Rather, plasmin, a fibrinolytic enzyme formed in response to thrombin generation and clot formation, efficiently generates C5a. The findings were validated in an arterial thrombosis model in mice. These insights may be valuable in developing therapeutic strategies to limit thrombus formation.
Collapse
Key Words
- Complement
- FDP, fibrin degradation product
- FeCl3, ferric chloride
- Fibrinolysis
- IL-8, interleukin-8
- IVC, inferior vena cava
- Leukocytes
- MAC, membrane attack complex
- MCP1-1, monocyte chemoattracant protein-1
- NETs, neutrophil extracellular traps
- PAR1, protease activated receptor 1
- PPACK, Phe-Pro-Arg-chloromethylketone
- R751, arginine 751
- TAT, thrombin antithrombin
- Thrombin
- Thrombosis
- VFKck, Val-Phe-Lys-chloromethylketone
- VWF, von Willebrand factor
- tPA, tissue-type plasminogen activator
Collapse
Affiliation(s)
- Jonathan H. Foley
- Centre for Blood Research, Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, LSC4306, Vancouver V6T 1Z3, Canada
- Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom
- Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Trust, London, United Kingdom
| | - Bethany L. Walton
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 819 Brinkhous-Bullitt Building, CB# 7525, Chapel Hill, NC 27599-7525, USA
| | - Maria M. Aleman
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 819 Brinkhous-Bullitt Building, CB# 7525, Chapel Hill, NC 27599-7525, USA
| | - Alice M. O'Byrne
- Centre for Blood Research, Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, LSC4306, Vancouver V6T 1Z3, Canada
| | - Victor Lei
- Centre for Blood Research, Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, LSC4306, Vancouver V6T 1Z3, Canada
| | - Micaela Harrasser
- Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom
| | - Kimberley A. Foley
- Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Canada
| | - Alisa S. Wolberg
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 819 Brinkhous-Bullitt Building, CB# 7525, Chapel Hill, NC 27599-7525, USA
| | - Edward M. Conway
- Centre for Blood Research, Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, LSC4306, Vancouver V6T 1Z3, Canada
- Corresponding author at: Centre for Blood Research, 4306-2350 Health Sciences Mall, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.Centre for Blood Research4306-2350 Health Sciences MallUniversity of British ColumbiaVancouverBCV6T 1Z3Canada
| |
Collapse
|
6
|
Abstract
Adipose tissue remodeling occurs in obesity, characterized by adipocyte hypertrophy and increased infiltration of macrophages which also shift to a proinflammatory phenotype. Factors derived from these macrophages significantly alter adipocyte function, such as repressing adipogenesis, inducing inflammatory response and desensitizing insulin action. As macrophages produce a cocktail of inflammatory signals, identifying the key factors that mediate the detrimental effects may offer effective therapeutic targets. IL-1β, a major cytokine produced largely by macrophages, is implicated in the development of obesity-associated insulin resistance. In this article, we discuss recent advances in our understanding of the role of IL-1β in macrophage-adipocyte crosstalk in obesity. IL-1β impairs insulin sensitivity in adipose tissue by inhibition of insulin signal transduction. Blocking the activity of IL-1β, its receptor binding or production improves insulin signaling and action in human adipocytes. This is in parallel with a reduction in macrophage-stimulated proinflammatory profile and lipolysis. Targeting IL-1β may be beneficial for protecting against obesity-related insulin resistance at the tissue and systemic levels.
Collapse
Key Words
- Akt, protein kinase B
- CCL5, chemokine (C-C motif) ligand-5
- GLUT4, glucose transporter 4
- IL-1Ra, interleukin-1 receptor antagonist
- IL-1β, interleukin-1β
- IL-6, interleukin-6
- IL-8, interleukin-8
- IRS1, insulin receptor substrate 1
- MC, macrophage-conditioned
- MCP-1, monocyte chemotactic protein-1
- NFκB, nuclear factor of κ light polypeptide gene enhancer in B-cells
- NLRP3, nucleotide-binding oligomerization domain
- PI3K, phosphoinositide-3-kinase
- SVF, stromal vascular fraction
- TNFα, tumour necrosis factor-alpha
- adipocyte
- adipose tissue
- chemokine
- cytokine
- domain-containing protein 3
- inflammation
- insulin resistance
- interleukin-1β
- leucine-rich repeat and pyrin
- macrophage
- obesity
Collapse
|
7
|
Sun K, Fan J, Han J. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. Acta Pharm Sin B 2015; 5:8-24. [PMID: 26579420 PMCID: PMC4629119 DOI: 10.1016/j.apsb.2014.11.002] [Citation(s) in RCA: 144] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 10/22/2014] [Accepted: 10/28/2014] [Indexed: 01/22/2023] Open
Abstract
Ischemic stroke and ischemia/reperfusion (I/R) injury induced by thrombolytic therapy are conditions with high mortality and serious long-term physical and cognitive disabilities. They have a major impact on global public health. These disorders are associated with multiple insults to the cerebral microcirculation, including reactive oxygen species (ROS) overproduction, leukocyte adhesion and infiltration, brain blood barrier (BBB) disruption, and capillary hypoperfusion, ultimately resulting in tissue edema, hemorrhage, brain injury and delayed neuron damage. Traditional Chinese medicine (TCM) has been used in China, Korea, Japan and other Asian countries for treatment of a wide range of diseases. In China, the usage of compound TCM preparation to treat cerebrovascular diseases dates back to the Han Dynasty. Even thousands of years earlier, the medical formulary recorded many classical prescriptions for treating cerebral I/R-related diseases. This review summarizes current information and underlying mechanisms regarding the ameliorating effects of compound TCM preparation, Chinese materia medica, and active components on I/R-induced cerebral microcirculatory disturbances, brain injury and neuron damage.
Collapse
Key Words
- 8-OHdG, 8-hydroxydeoxyguanosine
- AIF, apoptosis inducing factor
- AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- AP-1, activator protein-1
- Antioxidant
- Asp, aspartate
- BBB, brain blood barrier
- BMEC, brain microvascular endothelial cell
- BNDF, brain-derived neurotrophic factor
- Brain blood barrier
- CAT, catalase
- CBF, cerebral blood flow
- COX-2, cyclooxygenase-2
- Cav-1, caveolin-1
- DHR, dihydrorhodamine 123
- DPPH, 1,1-diphenyl-2-picrylhydrazyl radical 2,2-diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl
- ERK, extracellular signal-regulated kinase
- GABA, γ-aminobutyric acid
- GRK2, G protein-coupled receptor kinase 2
- GSH, glutathione
- GSH-Px, glutathione peroxidase
- GSSH, glutathione disulfide
- Glu, glutamate
- Gly, glysine
- HE, hematoxylin and eosin
- HIF, hypoxia-inducible factor
- HPLC, high performance liquid chromatography
- Hyperpermeability
- I-κBα, Inhibitory κBα
- I/R, ischemia-reperfusion
- ICAM-1, intercellular adhesion molecule-1
- IL-10, interleukin-10
- IL-1β, interleukin-1β
- IL-8, interleukin-8
- Ischemia/reperfusion
- JAM-1, junctional adhesion molecule-1
- JNK, Jun N-terminal kinase
- LDH, lactate dehydrogenase
- Leukocyte adhesion
- MAPK, mitogen activated protein kinase
- MCAO, middle cerebral artery occlusion
- MDA, malondialdehyde
- MMPs, matrix metalloproteinases
- MPO, myeloperoxidase
- MRI, magnetic resonance imaging
- NADPH, nicotinamide adenine dinucleotide phosphate
- NF-κB, nuclear factor κ-B
- NGF, nerve growth factor
- NMDA, N-methyl-d-aspartic acid
- NO, nitric oxide
- NSC, neural stem cells
- Neuron
- OGD, oxygen-glucose deprivation
- PARP, poly-ADP-ribose polymerase
- PMN, polymorphonuclear
- RANTES, regulated upon activation normal T-cell expressed and secreted
- ROS, reactive oxygen species
- SFDA, state food and drug administration
- SOD, superoxide dismutase
- TBARS, thiobarbituric acid reactive substance
- TCM, traditional Chinese medicine
- TGF-β1, transforming growth factor β1
- TIMP-1, tissue inhibitor of metalloproteinase-1
- TNF-α, tissue necrosis factor-α
- TTC, 2,3,5-triphenyltetrazolium chloride
- TUNEL, terminal-deoxynucleoitidyl transferase mediated nick end labeling
- Tuj-1, class III β-tublin
- VCAM-1, vascular adhesion molecule-1
- VEGF, vascular endothelial growth factor
- ZO-1, zonula occludens-1
- bFGF, basic fibroblast growth factor
- cAMP, cyclic adenosine monophosphate
- hs-CRP, high-sensitivity C-reactive protein
- iNOS, inducible nitric oxide synthase
- rtPA, recombinant tissue plasminogen activator
Collapse
|
8
|
Abstract
Diarrhea causes substantial morbidity and mortality in children in low-income countries. Although numerous pathogens cause diarrhea, the etiology of many episodes remains unknown. Serratia marcescens is incriminated in hospital-associated infections, and HIV/AIDS associated diarrhea. We have recently found that Serratia spp. may be found more commonly in the stools of patients with diarrhea than in asymptomatic control children. We therefore investigated the possible enteric pathogenicity of S. marcescens in vitro employing a polarized human colonic epithelial cell (T84) monolayer. Infected monolayers were assayed for bacterial invasion, transepithelial electrical resistance (TEER), cytotoxicity, interleukin-8 (IL-8) release and morphological changes by scanning electron microscopy. We observed significantly greater epithelial cell invasion by S. marcescens compared to Escherichia coli strain HS (p = 0.0038 respectively). Cell invasion was accompanied by reduction in TEER and secretion of IL-8. Lactate dehydrogenase (LDH) extracellular concentration rapidly increased within a few hours of exposure of the monolayer to S. marcescens. Scanning electron microscopy of S. marcescens-infected monolayers demonstrated destruction of microvilli and vacuolization. Our results suggest that S. marcescens interacts with intestinal epithelial cells in culture and induces dramatic alterations similar to those produced by known enteric pathogens.
Collapse
Affiliation(s)
- John B Ochieng
- Department of Pediatrics; University of Virginia School of Medicine; Charlottesville, VA USA,Kenya Medical Research Institute/Centers for Disease Control and Prevention (KEMRI/CDC); Kisumu, Kenya,Department of Biomedical Science and Technology; Maseno University; Maseno, Kenya
| | - Nadia Boisen
- Department of Pediatrics; University of Virginia School of Medicine; Charlottesville, VA USA
| | - Brianna Lindsay
- Department of Epidemiology and Public Health; University of Maryland School of Medicine; Baltimore, MD USA
| | - Araceli Santiago
- Department of Pediatrics; University of Virginia School of Medicine; Charlottesville, VA USA
| | - Collins Ouma
- Department of Biomedical Science and Technology; Maseno University; Maseno, Kenya
| | - Maurice Ombok
- Kenya Medical Research Institute/Centers for Disease Control and Prevention (KEMRI/CDC); Kisumu, Kenya
| | - Barry Fields
- Global Disease Detection Division; Centers for Disease Control and Prevention; Nairobi, Kenya
| | - O Colin Stine
- Department of Epidemiology and Public Health; University of Maryland School of Medicine; Baltimore, MD USA
| | - James P Nataro
- Department of Pediatrics; University of Virginia School of Medicine; Charlottesville, VA USA,Correspondence to: James P Nataro;
| |
Collapse
|